Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. - Wikidata - awgldk - TriplyDB

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

http://www.wikidata.org/entity/Q36754434

about

Response mechanisms of bacterial degraders to environmental contaminants on the level of cell walls and cytoplasmic membrane Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.Purification of a 54-kilodalton protein (OprJ) produced in NfxB mutants of Pseudomonas aeruginosa and production of a monoclonal antibody specific to OprJ Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori.nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients.Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

P2860

Q27012745-571FEAEC-E759-4576-996A-4A823564A6F2 Q35111809-745FF30D-45EB-40B3-9961-5D87089174ED Q35117101-8A2EBE17-CE9C-4A8C-A71D-951F273B28C5 Q35816058-C9DD69EB-AB60-4C83-A37D-E528D11733E1 Q39778896-DBD2275A-550C-4A3B-BBF3-EBEFA8B95AB3 Q39779448-A26A84E5-DB07-4A19-8E2B-386B1BE0360C Q40188725-4D4FE58A-A5CB-4753-9645-424867349B7A Q40286229-E3F69516-CF7A-4C3E-8AF2-2973A7BB6C73 Q40633555-0799FCDC-3143-4986-99C4-1A4F09578794

P2860

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

http://www.wikidata.org/entity/Q36754434

description

1991 nî lūn-bûn

@nan

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

1991年论文

@zh

1991年论文

@zh-cn

name

Persistence mechanisms in Pseu ...... ergoing ciprofloxacin therapy.

@en

type

label

Persistence mechanisms in Pseu ...... ergoing ciprofloxacin therapy.

@en

prefLabel

Persistence mechanisms in Pseu ...... ergoing ciprofloxacin therapy.

@en

P1433

Q36754434-9BB515C2-53D8-4DA1-B836-E2CE53CE2430

P1476

Q36754434-7D4D1AE8-8168-44B1-8A3F-7D289E5BF448

P2093

Q36754434-37E939EF-F150-40D0-A3C3-E0AEAAF87B2B

Q36754434-5FE0933B-FD7F-47EF-8EDD-E6829D6A764A

Q36754434-79D3739E-A1FF-4164-B02C-5AD9C0FCF945

Q36754434-8EAF8FA2-7A7C-4902-9FEA-47EE3A1BB27A

Q36754434-A5D0C7C5-1842-4B81-B1B8-B3402DEEAF6E

P2860

Q36754434-0A7AEB06-8016-4E97-8C35-FE0DB4AE78BD

Q36754434-0E092A36-7839-4314-9C57-1660CF1070D0

Q36754434-189285D8-63C2-45C3-BF73-D73AB935A265

Q36754434-1C99F02B-8E2E-4023-AB68-8933A3300193

Q36754434-1FDE2D31-017E-455B-8703-DC905A03BB43

Q36754434-2606B5BE-3BAB-4C9D-875B-08F99C22E6DB

Q36754434-2F2FAAB9-672E-491E-A971-2172FE4F2317

Q36754434-2FD2C65A-F1C3-48EE-AAB6-ED0BAF1F659C

Q36754434-31336D17-FD42-4F9D-BDAB-FAA94827E7AD

Q36754434-38CBC6D0-631E-4A52-8428-7AAE09B6550D

P304

Q36754434-5D94593C-9EE3-4DCB-949A-9277E152B761

P31

Q36754434-1F2ACBDC-3371-404F-B0E9-960EC5D38714

P356

Q36754434-EBA012D1-1738-46BB-BCEA-A5A281E81165

P407

Q36754434-C73A03AB-7A78-4F01-A2B7-9EF3E2AF3F66

P433

Q36754434-361565FE-F9D2-4E5E-950F-3E5536E3DDA9

P478

Q36754434-A979DB96-1EA0-4BD8-812E-619252270C78

P577

Q36754434-E3551CDF-8526-40F1-BA75-9A3BA4D45028

P5875

Q36754434-B12423BE-6A1D-45B3-999D-80E059C8818D

P698

Q36754434-F3F75EB8-33EC-4E34-96CF-6A282BFC2F07

P921

Q36754434-343056B0-79AC-4C2D-8558-A978DA764BFF

P932

Q36754434-169B0F47-241B-4E25-9FDB-D381AB6CFA20

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Persistence mechanisms in Pseu ...... ergoing ciprofloxacin therapy.

@en

P2093

Bryan LE

http://www.w3.org/2001/XMLSchema#string

Diver JM

http://www.w3.org/2001/XMLSchema#string

Rabin HR

http://www.w3.org/2001/XMLSchema#string

Schollaardt T

http://www.w3.org/2001/XMLSchema#string

Thorson C

http://www.w3.org/2001/XMLSchema#string

P2860

Protein measurement with the Folin phenol reagent

Outer membrane proteins responsible for the penetration of beta-lactams and quinolones in Pseudomonas aeruginosa

DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin

Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.

Broad-host-range gyrase A gene probe.

Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin

Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens

P304

1538-1546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.35.8.1538

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

1991-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21498603

http://www.w3.org/2001/XMLSchema#string

P698

1656866

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

245215

http://www.w3.org/2001/XMLSchema#string